The United States stock market has recently experienced a surge, with major indices like the Dow Jones and Nasdaq Composite showing significant gains amid optimism over reduced China tariffs and ...

Scotiabank analyst Greg Harrison lowered the firm’s price target on Travere Therapeutics (TVTX) to $30 from $32 and keeps an Outperform rating ...

Canaccord analyst Edward Nash raised the firm’s price target on Travere Therapeutics (TVTX) to $47 from $45 and keeps a Buy rating on the ...

Ratings for Travere Therapeutics (NASDAQ:TVTX) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick ...

Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) – Wedbush issued their Q1 2026 EPS estimates for shares of Travere Therapeutics in a research report issued on Wednesday, April 16th.

Today, the American Kidney Fund (AKF) announces its 2025 Class of Corporate Members who serve as strategic partners in AKF’s Corporate Membership Program. Corporate Members provide vital support to ...

The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new employee’s continued service relationship with Travere through the applicable ...

Travere Therapeutics (NASDAQ:TVTX – Free Report) had its target price lifted by Canaccord Genuity Group from $45.00 to $47.00 in a research note issued to investors on Thursday morning ...

BOSTON -- Patients with focal segmental glomerulosclerosis (FSGS) achieved some degree of proteinuria remission more often ...

The latest analyst rating for Travere Therapeutics (NASDAQ:TVTX) was provided by Guggenheim, and Travere Therapeutics reiterated their buy rating. The last upgrade for Travere Therapeutics Inc ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present three abstracts, including one late-breaking oral presentation, at the upcoming National Kidney Foundation ...